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Abstract
The transmembrane domain proteins of the claudin superfamily are the major structural components of cellular tight
junctions. One family member, claudin-1, also associates with tetraspanin CD81 as part of a receptor complex that is
essential for hepatitis C virus (HCV) infection of the liver. To understand the molecular basis of claudin-1/CD81 association
we previously produced and purified milligram quantities of functional, full-length CD81, which binds a soluble form of HCV
E2 glycoprotein (sE2). Here we report the production, purification and characterization of claudin-1. Both yeast membrane-
bound and detergent-extracted, purified claudin-1 were antigenic and recognized by specific antibodies. Analytical
ultracentrifugation demonstrated that extraction with n-octyl-b-D-glucopyranoside yielded monodispersed, dimeric pools of
claudin-1 while extraction with profoldin-8 or n-decylphosphocholine yielded a dynamic mixture of claudin-1 oligomers.
Neither form bound sE2 in line with literature expectations, while further functional analysis was hampered by the finding
that incorporation of claudin-1 into proteoliposomes rendered them intractable to study. Dynamic light scattering
demonstrated that claudin-1 oligomers associate with CD81 in vitro in a defined molar ratio of 1:2 and that complex
formation was enhanced by the presence of cholesteryl hemisuccinate. Attempts to assay the complex biologically were
limited by our finding that claudin-1 affects the properties of proteoliposomes. We conclude that recombinant, correctly-
folded, full-length claudin-1 can be produced in yeast membranes, that it can be extracted in different oligomeric forms that
do not bind sE2 and that a dynamic preparation can form a specific complex with CD81 in vitro in the absence of any other
cellular components. These findings pave the way for the structural characterization of claudin-1 alone and in complex with
CD81.
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Introduction
Hepatitis C virus (HCV) is a member of the Flaviviridae family.
This important human pathogen specifically infects the liver. At
present there is no HCV vaccine and although a number of drugs
targeting HCV replicase enzymes are in development, recent trials
have shown a rapid appearance of drug-resistant viruses [1,2]. The
conserved nature of HCV entry into host cells offers an alternative
and attractive target for therapeutic intervention.
HCV initiates infection by attaching to the cell surface followed
by clathrin-dependent internalization of virus particles; current
evidence supports a role for scavenger receptor class B member I
(SR-BI), tetraspanin CD81 and tight junction proteins claudin-1
and occludin in coordinating this process (reviewed in [3]). SR-BI
and CD81 bind HCV-encoded E1E2 glycoproteins with high
affinity and have been reported to play a role in particle
attachment to the cell [4,5]. In contrast, there is limited
information on whether claudin-1 or occludin interacts directly
with HCV. The essential role of claudin-1 in the late stages of
HCV entry [6] suggests that there may be a requirement for the
virus to bind receptor proteins in a defined sequence or that
claudin-1 has another, as yet undetermined, function.
The claudin superfamily of four transmembrane domain (4TM)
proteins oligomerize to form strands that comprise cellular tight
junctions [7], thereby generating the seal required to maintain
cellular homeostasis. Interactions between the first and second
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claudin extracellular loops (EC1 and EC2; Fig. 1A) allow protein
associations both within the plasma membrane of a single cell and
between adjacent cells (reviewed in [8]); Fo¨rster resonance energy
transfer (FRET) between tagged molecules suggests that protein
dimers are the primary building block(s) of claudin strands [8]. We
[9,10,11] and others [12] have reported that claudin-1 associates
with tetraspanin CD81; this receptor complex is present at the
basolateral membrane of hepatoma cells [13] and is essential for
HCV entry in vitro [10]. Inhibiting protein kinase A [14] or
activating epidermal growth factor accessory protein [15] limits
claudin-1/CD81 complex formation and HCV entry. Further-
more, anti-claudin-1 antibodies inhibit HCV infection by reducing
claudin-1 association with CD81 without perturbing tight junction
integrity [16].
Having established the biological relevance of claudin-1
interaction with CD81, our aim is to characterize these proteins
in vitro. Since primary human hepatocytes and the majority of
human hepatoma cells express all four receptor proteins, and
siRNA silencing approaches are frequently partial, it is difficult to
study the role of claudin-1 in the HCV internalisation process in
mammalian cells. We have therefore focused on purifying
recombinant, full-length protein components of the HCV receptor
complex; studies on CD81 have highlighted important differences
in the interaction of HCV with full-length, cell-expressed forms of
CD81 and recombinant truncated forms of the soluble second
extracellular loop (EC2) [17]. For example a soluble, mutant form
of EC2 (F150S) does not interact with HCV sE2, while mutation
of the same residue in full-length, cell-expressed CD81 has
minimal effects on HCV sE2 binding [18]. These results suggest
that EC2 has a more robust structure in the full-length tetraspanin
and, together with other data, indicate that regions in EC1 or the
transmembrane domains may play a role in CD81 dimerisation
[19].
We previously reported the purification of recombinant, full-
length human CD81 from the methylotrophic yeast Pichia pastoris
[20]: monomers, dimers and higher oligomers of CD81 were
observed in recombinant P. pastoris membranes comparable with
endogenous protein in mammalian membranes. Immunofluores-
cent and flow cytometric staining of P. pastoris protoplasts with
monoclonal antibodies specific for CD81 EC2 demonstrated
comparable conformation of the recombinant and native mole-
cules. Recombinant CD81 isolated in a monodispersed form using
n-octyl-b-D-glucopyranoside (bOG), as determined by analytical
ultracentrifugation (AUC), was shown to interact with HCV sE2,
representing the first biophysical characterization of a functional,
full-length, recombinant tetraspanin [20].
Here we report the production of milligram quantities of
recombinant human claudin-1 using the yeast, P. pastoris. Yeast
protoplasts expressing claudin-1 bound an antibody specific for a
conformation-dependent epitope expressed on human hepato-
cytes, suggesting a native protein conformation. Claudin-1 could
be isolated from yeast membranes in various oligomeric forms,
dependent upon the detergent used. When isolated with bOG, it
was monodispersed and dimeric, while isolation with profoldin-8
or n-decylphosphocholine (foscholine-10) resulted in dynamic
mixtures of oligomers. When oligomeric preparations were
reconstituted into liposomes, the resulting proteoliposomes inhib-
ited HCV infection of hepatoma cells in a dose-dependent
manner. Claudin-1-containing proteoliposomes also inhibited the
infectivity of lentiviral pseudotypes expressing HCV E1E2
glycoproteins (HCVpp) and, unexpectedly, vesicular stomatitis
virus expressing glycoprotein G (VSV-Gpp). In contrast, CD82-
containing proteoliposomes had no effect on HCVpp or VSV-
Figure 1. Claudin-1 forms monomers and higher order structures in yeast membranes. (A) A schematic representation of the claudin-1
protein produced in this study. The membrane is represented in grey (the extra- and intracellular sides are labeled), the extracellular loops, EC1 and
EC2, are marked and the His6 tag is indicated in the carboxy-terminal tail. The predicted molecular mass is 23.7 kDa. (B) Recombinant claudin-1 in P.
pastoris membranes forms monomers, dimers and trimers as determined by non-reducing SDS-PAGE (1 mg protein loaded per well). Endogenous
claudin-1 in Huh-7.5 hepatoma cells was analyzed for comparison (5 mg protein loaded per well) showing monomers and oligomers. Protein
concentrations in the two cell types are different because the yeast cells overexpress recombinant claudin-1; this does not affect the antigenicity of
the protein, as shown in Fig. 3. Molecular size markers are indicated in the intervening lane.
doi:10.1371/journal.pone.0064517.g001
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Gpp, indicating that proteoliposomes are not tractable to study the
biological function of claudin-1. In the absence of a suitable
biological assay, the known interaction of claudin-1 with CD81
was therefore examined in vitro.
Using dynamic light scattering (DLS), dynamic preparations of
claudin-1 (in foscholine-10) were demonstrated to associate with
CD81 in a defined molar ratio (1:2) of claudin-1:CD81 and in the
absence of any other cellular components. In contrast, mono-
dispersed claudin-1 (in bOG) failed to associate with CD81.
Claudin-1/CD81 complexes were stabilized by the presence of
cholesteryl hemisuccinate (CHEMS) consistent with literature
reports that cholesterol promotes complex formation in mamma-
lian cells [3]. In summary, this study represents the first in-depth
characterization of recombinant, full-length claudin-1; the data
presented here should accelerate the structural analysis of the
claudin superfamily and promote structure-aided design of
therapeutic agents that target the early entry step of the HCV
lifecycle.
Results
Full-length human claudin-1 is oligomeric in yeast
membranes
Claudin-1 was expressed in P. pastoris cells using our previously
reported protocol for CD81 [20]. SDS-PAGE analysis of human
claudin-1 expressed in yeast membranes showed diverse oligo-
meric states, as previously reported for CD81 [20]. The oligomeric
pools of claudin-1 observed in yeast membranes were comparable
with endogenous claudin-1 observed in Huh-7.5 hepatoma cells
under non-reducing conditions (Fig. 1B).
Conformation-dependent antibodies that recognize native
claudin-1 and, as a control, CD81 [21] were used as tools to
probe the conformation of the yeast-expressed protein. In order to
evaluate antibody binding by flow cytometry and confocal
imaging, protoplasts were generated for each P. pastoris strain by
enzymatically digesting the cell wall. Antibodies bound specifically
to claudin-1 (33.6%) (Fig. 2A, B). In contrast, X33 control
protoplasts (lacking heterologous protein expression) did not show
significant antibody binding (Fig. 2A, B). These data provide
evidence for correctly folded, antigenic claudin-1 in the yeast
membrane.
Biophysical characterization of recombinant human
claudin-1
Claudin-1 (23.7 kDa), CD81 (26.7 kDa) and the related
tetraspanin CD82 (which is not a component of the HCV
receptor complex; 30.6 kDa) were extracted from yeast mem-
branes with bOG (Fig. 3A), a preferred detergent for biophysical
studies [20,22]. The three proteins were purified by nickel-affinity
chromatography and size exclusion chromatography. Claudin-1
appeared as a dimer by reducing SDS-PAGE (Fig. 3A), whereas
CD81 [20] and CD82 ran as monomers. AUC demonstrated
claudin-1 was in a monodispersed oligomeric state (Fig. 3B).
Antigenic characterization of purified, bOG-extracted claudin-1
and CD81 demonstrated reactivity with antibodies specific for the
proteins and the hexahistidine tag (Fig. 3C).
Since claudin-1 formed higher molecular weight oligomeric
structures in mammalian cell membranes (Fig. 1B), we screened
further detergents in an attempt to isolate different oligomeric
states from yeast membranes. Protein solubility was assessed in a
range of micelles containing short-chain lipids and detergents with
various acyl chains, head groups and amphipathic polymers
including: n-dodecyl-b-D-maltopyranoside (DDM); foscholine-10;
n-dodecylphosphocholine (DPC); n-dodecylphosphocholine-cho-
lesterolhemisuccinate (DPC/CHS); 4-cyclohexyl-1-butylphospho-
choline (cyclofos-4); 2,6-dimethyl-4-heptylphosphocholine; N,N-
dimethyldodecan-1-amine oxide (LDAO); pentaethyleneglycol-n-
octylether (C8E5); docosaethyleneglycol-monohexadecylether
(Brij-58) and the profoldin membrane protein extraction solutions
1–12. Profoldin-8, a proprietary detergent formulation, most
efficiently extracted oligomeric claudin-1 from yeast membranes.
The circular dichroism (CD) spectrum of this material was
consistent with profoldin-8-solubilized claudin-1 being folded in a
predominantly a-helical state, with signature peaks at 208 nm and
222 nm. The corresponding AUC trace revealed two species
(Fig. 3D), which could not be isolated by size exclusion
chromatography. These data are consistent with the oligomeric
states being in a dynamic equilibrium.
Biological characterization of recombinant human
claudin-1
To investigate whether purified claudin-1 can associate with
HCV glycoproteins, monodispersed (bOG-extracted and purified)
and oligomeric (profoldin-8-extracted and purified) forms were
assessed for their ability to bind HCV sE2. Neither form of
claudin-1 bound the virus glycoprotein (Fig. 4). In contrast, CD81
bound HCV sE2 as previously reported (Fig. 4; [20]). These data
suggest that claudin-1 does not interact directly with HCV-
encoded glycoprotein, as previously observed in human hepato-
cyte-derived cell lines [23]. For subsequent experiments, a
replacement for the detergent profoldin-8 was sought on account
of its proprietary composition: foscholine-10 also extracted
oligomeric claudin-1 with the same properties as profoldin-8
(Fig. 5A), whilst being chemically defined.
Surfactants, such as the detergents used in our study, are not
compatible with mammalian cell viability. To study the biological
activity of claudin-1 in vivo, the purified protein and tetraspanin
CD82 were therefore reconstituted into proteoliposomes [24]. We
assessed protein incorporation by measuring anti-claudin-1, anti-
CD82 or anti-His reactivity by Western blotting and ELISA
(Fig. 5A). Since the hexahistidine tag is located at the carboxy-
terminus of both proteins, we compared antibody reactivity to
native and detergent-solubilized proteoliposome preparations to
assess protein orientation. We routinely observed an increase in
anti-His reactivity with detergent solubilized proteoliposomes
compared with untreated ones (data not shown) suggesting that
the proteins are incorporated in both orientations, as might be
anticipated.
Proteoliposome preparations were normalized for equivalent
protein incorporation (as determined by His OD450 units) prior to
evaluating their effect on HCV infection. Claudin-1-containing
proteoliposomes inhibited HCV strain J6/JFH infection of Huh-
7.5 hepatoma cells in a dose-dependent manner, whereas CD82-
containing control proteoliposomes had no effect (Fig. 5B). To
determine whether claudin-1-containing proteoliposomes inhibit
HCV infection at the level of particle entry, their effect on HCVpp
and control VSV-Gpp was evaluated. Claudin-1-containing
proteoliposomes inhibited HCVpp and VSV-Gpp infection
(Fig. 5C). Control proteoliposomes (containing CD82) had no
effect on HCVpp or VSV-Gpp infection (Fig. 5C). These data
suggest that the presence of claudin-1 in proteoliposomes alters
pseudoparticle uptake per se and that this modulation is not specific
to HCV entry.
Claudin-1 oligomers can associate with CD81 in vitro
In the absence of a tractable assay to study the biological
function of claudin-1, we measured its ability to interact with
CD81 in vitro in the absence of host cell proteins, lipids or other
Characterization of Recombinant Claudin-1
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cellular components. In vitro mixing was first performed with bOG-
solubilized claudin-1 since this preparation had been demonstrat-
ed to be monodispersed (Fig. 3B). Following a 30 min incubation,
1:1 and 1:2 molar ratios of bOG-solubilized claudin-1 and CD81,
claudin-1 and CD82 or CD81 and CD82 were analyzed by size
exclusion chromatography. In all cases, there was no substantial
change in the elution profile compared with pure proteins alone,
suggesting that no complexes had formed. Potential interactions
were explored further using oligomeric claudin-1, monodispersed
CD81 and, as a control, CD82.
Since tetraspanins are found in cholesterol-enriched membrane
microdomains, where they interact with each other [25] and other
proteins [26], we designed in vitro mixing experiments to examine
the association of purified claudin-1 and CD81, claudin-1 and
CD82 or CD81 and CD82 in different molar ratios (9:1, 2:1, 1:1,
1:2 and 1:9) in the presence or absence of CHEMS; an acidic
cholesteryl ester that self-assembles into bilayers in alkaline and
neutral aqueous media [27]. DLS was used to analyze the time-
dependent intensity fluctuations of scattered light in each mixture
of solubilized proteins (including any interactions or complexes
formed).
Within the DLS intensity fluctuation data, information is
contained on the time scale of movement of all particles in
solution and, importantly, their size distribution profile [28]. As
previously described [29], hydrodynamic radii (RH) could be
calculated for the particles contained in all mixtures analyzed
Figure 2. Antigenicity of human claudin-1 in yeast protoplasts. Conformation-dependent antibodies specific for claudin-1 (R&D Systems)
and, as a control, CD81 (2s131) were used as tools to probe the antigenicity of yeast-expressed claudin-1. Secondary antibodies were Alexa Fluor 488
goat anti-mouse IgG (H+L) and Alexa Fluor 633 goat anti-rat IgG (H+L) (Invitrogen). The parental X33 strain with no heterologous protein expression
was used as a negative control. (A) Fluorescence activated cell sorting shows specific antibody binding with anti-claudin-1 antibodies for X33 (0.93%)
and claudin-1 (33.6%) protoplasts. For anti-CD81 antibodies, the corresponding values are X33 (1.9%) and claudin-1 (0.93%). (B) Confocal imaging
shows specific antibody binding for protoplasts expressing human claudin-1. The protoplasts were immuno-flourescently labelled with anti-claudin-1
or a relevant isotype control. Settings were optimized for each fluorescent protein to obtain the highest signal to noise ratio, while controlling for
cross talk. Relevant isotype control antibodies did not bind.
doi:10.1371/journal.pone.0064517.g002
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(Table 1). To determine the diffusion coefficient, the CONTIN
algorithm [30] was used to analyze the auto-correlation function
(ACF). The Stoke-Einstein equation [31] was used to calculate RH
from these data. Two particle distributions were observed; one
with RH,10 nm and one with RH$10 nm. For claudin-1
solubilized with foscholine-10 in the presence or absence of
CHEMS, the mean particle hydrodynamic radius of the smaller
particle was 4.0 nm (Fig. 6C; Table 1). This corresponds to a
molecular weight of approximately 77 kDa, consistent with a
dimer; the molecular mass of claudin-1 is 23 kDa, while that of a
foscholine-10 micelle, as determined by DLS, is 28 kDa [32]. The
larger particle was defined by a peak which was broader than that
for bOG-solubilized CD81 or bOG-solubilized CD82 (Fig. 6A,
B), consistent with purified claudin-1 being composed of a
dynamic mixture of oligomeric states (Fig. 3D; Table 1). Peak
broadening in excess of 100 nm (Fig. 6C) was even more
pronounced after 6 h of measurement. For all claudin-1:CD81
ratios, except for claudin-1:CD81 1:2, the distributions of particle
Figure 3. Biophysical analysis of purified claudin-1. (A) Coomassie-stained SDS-PAGE gel showing CD81 (lane 1 containing 2.4 mg protein), a
control 4TM protein (CD82; lane 2; 1.5 mg protein) and claudin-1 (lane 3; 1.2 mg protein) solubilised in bOG and eluted from a nickel affinity column.
Claudin-1 (highlighted with an arrow) runs as an apparent dimer. Molecular size markers are indicated. (B) Analytical ultracentrifugation trace for
claudin-1 in bOG micelles collected on a Proteome Lab XL-I instrument. (C) ELISA data based on OD450 readings showing antibody reactivity (n = 2;
error bars are the standard deviation) for bOG-extracted and purified claudin-1, CD81 and CD82. (D) Analytical ultracentrifugation trace for claudin-1
in profoldin-8 micelles collected on a Proteome Lab XL-I instrument. Data were analyzed using the continuous distribution, c(s), model, which
calculates the distribution of sedimenting species taking into account their diffusion. Shown are the mass distributions of particles within the
samples, c(s), as a function of the sedimentation co-efficient (S; measured in units of Svedberg, with 1 S = 10213 s). Inset is a silver-stained SDS-PAGE
gel showing claudin-1 solubilized in profoldin-8 and eluted from a nickel affinity column. Monomers and oligomers are highlighted with arrows.
doi:10.1371/journal.pone.0064517.g003
Figure 4. Purified claudin-1 does not bind HCV E2. ELISA data
based on OD450 readings (n = 3; error bars are the standard deviation)
showing reactivity with HCV E2. Claudin-1 in both bOG micelles
(monodispersed) and profoldin-8 micelles (a dynamic mixture of
oligomers) were analyzed and compared with CD81 (a positive control
for HCV E2 binding) and CD82 (a negative control for HCV E2 binding).
A control GNA lectin gave an OD450 signal of 3.2960.04 in the presence
of HCV E2, and 0.0460.01 in its absence.
doi:10.1371/journal.pone.0064517.g004
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sizes were similar to the one observed for a non-interacting
mixture such as CD81/CD82 (Fig. 6E) or claudin-1/CD82
(Fig. 6F). For claudin-1:CD81 1:2, the distribution of particle
radii in solution was different: both with and without CHEMS, a
defined oligomeric species at ,30 nm appeared within 1 h of
mixing the proteins (Fig. 6D, Fig. 7; Table 1), which was not
observed for any other combination or ratio of 4TM proteins. The
relative abundance of the 30 nm complex also increased,
becoming dominant over 12 h (Fig. 6D, 7A). This suggests that
complex formation between claudin-1 and CD81 was only
possible in vitro at a specific molar ratio of 1 claudin-1: 2 CD81
and that the complex was stabilized by the presence of CHEMS
(Fig. 7B). These data provide evidence that dynamic pools of
claudin-1 associate with CD81 and that the receptor complexes
are stabilised in cholesteryl-enriched membranes. This occurs in
vitro in the absence of other HCV receptor or cellular components.
Discussion
Since no high resolution crystal structure of any full-length
HCV receptor component has been published, new approaches to
facilitate their biophysical characterization are required. In this
study we demonstrate that recombinant, correctly-folded, full-
length claudin-1 can be produced in yeast membranes, that it can
be extracted in different oligomeric forms that do not bind HCV
sE2 and that a dynamic preparation can complex with CD81 in
vitro at a defined molar ratio of 1:2. This event does not require
any other cellular component(s) and complexes are stabilized in
cholesteryl-enriched membranes.
Previous biophysical studies (using AUC and light scattering)
suggest that recombinant claudin-4 is in a dynamic equilibrium of
hexamers and other oligomers [33]. A hexameric structure aligns
with the low resolution structural analysis of the tetraspanin
uroplakins (UPs) Ia and Ib, which have been shown to comprise a
hexamer of heterodimers that form a crystalline 2D array in vivo of
approximately 16 nm particles (RH<8 nm) [34]. This dynamic
behavior is consistent with tight junction strand breakage and
reformation, which is important for barrier function. Our in vitro
data for purified recombinant claudin-1 in detergent micelles
suggest that dynamic populations of claudin-1 are capable of
rapidly forming complexes with CD81 that are stabilized in a
cholesteryl-enriched environment. Cholesterol is crucial for HCV
entry [35] and a 3D model of CD81 reveals an aromatic amino
acid cluster in the membrane that is typical of two cholesterol
binding sites [36]. Notably, tetraspanins are stabilized by the
cholesterol enrichment of microdomains [37] and mammalian
cells depleted of cholesterol show lower claudin-1/CD81 interac-
tion by FRET that is restored by cholesterol addition [3].
Figure 5. Biological analysis of claudin-1 in proteoliposomes. (A) Proteoliposome preparations containing claudin-1 or a control protein
(CD82) were diluted and evaluated for anti-His reactivity by ELISA; data are represented as optical density (OD) at 450 nm. Inset is an immunoblot of
foscholine-10 extracted claudin-1 stained with an anti-hexahistine tag antibody. Monomers and oligomers are highlighted with arrows.
Proteoliposome preparations were normalized for His OD units and evaluated for their effect on (B) HCV as well as (C) HCVpp and VSV-Gpp infectivity.
Data are expressed relative to untreated control virus infection.
doi:10.1371/journal.pone.0064517.g005
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We previously reported a 1:1 stoichiometry of the claudin-1/
CD81 complex in mammalian cells using FRET. To rationalise
this observation with our DLS data (Table 1), the tetraspanin
uroplakin model [34] and evidence that the fundamental
structural unit of CD81 [19] and claudins [38] is a dimer, we
propose the schematic representation of a possible claudin-1/
CD81 complex (Fig. 8). This scheme is based on stoichiometry
derived from low resolution cryo-electron crystallography data
[34] and is therefore speculative: seven uroplakin-like CD81
complexes (black), each containing six homodimers, are arranged
with 24 claudin-1 homodimers (red) to generate a symmetrical
particle, which fits with our data (RH = 30 nm; Table 1). The
resulting molar ratio of 24:42 claudin-1:CD81 is close to the
observed 1:2 ratio observed in our DLS experiments (Table 1). At
the center of the complex, 6 claudin-1 dimers are packed near 6
CD81 dimers, an arrangement that would account for our
previous FRET data [10] for dimers packed within approximately
10 nm of each other; at larger distances the FRET signal decreases
sharply as it has an inverse sixth power dependence on distance.
This hypothetical complex is consistent with a recent study
demonstrating that in mouse liver tissue, claudin-2 can be isolated
as a component of a high molecular weight protein complex with
claudin-1 and occludin [38] and that claudin-2 has been reported
to dimerize via transmembrane interactions [38].
Single particle tracking studies demonstrate that CD81 is highly
mobile in the membrane [39,40] and claudin-1 expression reduces
CD81 mobility (Harris, unpublished data). The data presented
here support a model whereby CD81 diffuses through the
membrane and is able to complex with claudin-1 on account of
its ability to exist in a dynamic equilibrium of homo-oligomeric
(Fig. 3D) and hetero-oligomeric (Table 1, Fig. 7, Fig. 8) forms.
At a molar ratio of claudin-1:CD81 of 1:2, a complex is formed
further consistent with reports of other high molecular weight
protein complexes containing claudin-1 [38].
To analyze the biological function of claudin-1 (and its
complexes), we generated proteoliposomes; recent advances in
the use of polymers to isolate membrane proteins and their
complexes in a biocompatible format may also offer a future
solution for studies of biological function [41]. Unexpectedly, we
found that the presence of claudin-1 in proteoliposomes altered
pseudoparticle uptake into hepatoma cells and that this modula-
tion was not specific to HCV (Fig. 5). Polyunsaturated ER-
targeting liposomes (PERLs) have also been demonstrated to be
anti-viral, affecting both the secretion and infectivity of HIV,
hepatitis B and hepatitis C viruses [42]. Cholesterol levels in the
plasma membrane of the host cell and the membrane of the
secreted virus were disrupted by PERLs [42]. Claudin-1-contain-
ing proteoliposomes, like PERLs, also appear to inhibit HCV
entry; since claudin-1 is required in the late stages of HCV cell
entry [6], it is possible that the internalization of claudin-1-
containing proteoliposomes causes this inhibition, although this
remains to be determined [35].
Both structural and functional analyses of recombinant claudin-
1 with CD81 and HCV are now required to identify the critical
amino acids defining HCV receptor form and function [6]. The
data presented here pave the way for the structural characteriza-
tion of wild-type and mutant forms of claudin-1, alone and in
complex with CD81, which may ultimately enable structure-aided
design of new therapeutic agents targeted at viral entry.
Materials and Methods
Production of recombinant claudin-1, CD81 and CD82
and protoplast formation
Recombinant, full-length 4TM proteins, with a hexahistidine
tag at the carboxy terminus, were produced in P. pastoris X33 cells
under the control of the AOX1 promoter using the pPICZB vector
(Invitrogen) [43,44], as previously described for CD81 [20,45].
The full-length CD81 protein used in this study was previously
produced in a form where six putative palmitoylation sites were
mutated to alanine [20]; this mutant form of CD81 binds the
HCV envelope [20,46] and permits viral entry [46]. Full-length
Table 1. Distribution of particle hydrodynamic radii (RH) derived from DLS measurements of purified recombinant claudin-1 and
CD81.
Protein Particle radius (RH; nm) Predicted oligomeric state
2 CHEMS + CHEMS
,10 nm .10 nm ,10 nm .10 nm
Claudin-1 in foscholine-10 4.0 (2.5; 0.6) 40 (40; 0.3) 4.0 (1.3; 0.8) 40 (20; 0.2) Dimer (4 nm) as well as higher oligomers/aggregates
(peak at 40 nm)
CD81 in bOG 6.0 (3.5; 1.0) – 6.5 (1.0; 1.0) 25 (6; 0.3) Dimer (6 nm) plus, in the presence of CHEMS, a distinct
peak at 25 nm
Claudin-1: CD81 (1:1) 4.6 (2.0; 1.0) 45 (40; 0.2) 5.0 (1.6; 1.0) 48 (23; 0.2) Dimer (4–5 nm) as well as higher oligomers/aggregates
(broad peak at .40 nm)
Claudin-1: CD81 (1:2) 4.2 (0.9; 0.9) 28 (9.0; 0.4) 4.0 (1.6; 0.3) 33 (9.0; 0.7) Dimer (4 nm) as well as a distinct oligomer (30 nm) which
is dominant in the presence of CHEMS; predicted to be
hexameric
Claudin-1: CD81 (2:1) 4.3 (1.7; 0.8) 42 (10; 0.2) 5.0 (1.0; 0.9) 68 (30; 0.2) Dimer (4–5 nm) as well as higher oligomers/aggregates
(broad peak at .40 nm)
Claudin-1: CD81 (1:9) 5.2 (1.4; 0.9) 48 (48; 0.3) 6.5 (2.6; 0.9) 70 (85; 0.2) Dimer (.5 nm) as well as higher oligomers/aggregates
(broad peak at .40 nm)
Claudin-1: CD81 (9:1) 4.5 (2.5; 0.8) 75 (30; 0.2) 4.0 (0.5; 1.0) 41 (10; 0.2) Dimer (.4 nm) as well as higher oligomers/aggregates
(peak at 40 nm similar to claudin-1 alone)
Values are reported after 12 h for particles with hydrodynamic radii ,10 nm or .10 nm, as defined by DLS peaks. Peak width at half height (nm) and relative peak
amplitude are reported in parentheses, respectively. Amplitude is relative to that of the corresponding CD81 peak in the absence of CHEMS. The radius of a foscholine-
10 micelle in solution, calculated from DLS measurements, is 2.560.6 nm [32]. For bOG-micelles, the value is 2.3–3.1 nm [54].
doi:10.1371/journal.pone.0064517.t001
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Figure 6. Oligomeric claudin-1 associates with CD81 at a specific molar ratio of 1:2. A plot of relative intensity of differently-sized particles
(RH reported in nm, derived from DLS measurements at room temperature) of claudin-1, CD81 or a control protein (CD82), alone or as mixtures,
solubilized in detergent micelles and in the presence of CHEMS. The data are the average of the first 10 measurements of the DLS experiment. Inset
are DLS heat maps, where the colour spectrum indicates the amplitude of the signal for a given hydrodynamic radius (RH) value as a function of time;
red is high- and blue is low amplitude. (A) CD81 in bOG. (B) CD82 in CD. (C) claudin-1 in foscholine-10; claudin-1 particles have a broad radial
distribution consistent with a dynamic pool of oligomers. (D) claudin-1 mixed with CD81 in a 1:2 molar ratio; a distinct 30 nm particle is highlighted
with a red asterisk. (E) CD82 mixed with CD81 in a 1:2 molar ratio; in addition to a dominant peak at 6 nm, some higher oligomers are present, which
do not form a distinct peak. (F) claudin-1 mixed with CD82 in a 1:2 molar ratio; in addition to a dominant peak at 6 nm, higher oligomers are present
at .40 nm.
doi:10.1371/journal.pone.0064517.g006
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claudin-1 and CD82 were wild-type. To generate protoplasts, a
mid-logarithmic phase aliquot of P. pastoris X33 cells producing the
relevant 4TM protein was re-suspended in 50 mM KH2PO4,
40 mM b-mercaptoethanol (adjusted to pH 7.2 with KOH) and
incubated for 30 min at 30uC, 150 rpm. The cell suspension was
diluted 1:1 with the same 50 mM phosphate buffer including 2.4
M sorbitol. Zymolyase 20T was added to a final concentration of
1 mg mL21 and the reaction was incubated for 90 min at 30uC,
150 rpm. After harvesting the protoplasts (5006 g, 5 min) and
washing them once, they were resuspended in a stabilizing buffer
(250 mM KCl, 10 mM CaCl2, 5 mM MgCl2, 5 mM MES
adjusted to pH 7.2 with Tris-base) supplemented with 1% glucose.
Fluorescent activated cell sorting
Protoplasts expressing recombinant claudin-1 or no heterolo-
gous protein were blocked in phosphate buffered saline (PBS) using
1% bovine serum albumin for 20 min at room temperature.
Protoplasts were washed in PBS and then incubated with primary
antibodies; anti-CD81 (2s131; [21]), anti-claudin-1 (R&D systems),
anti-His (Clontech) or a control isotype monoclonal antibody for
1 h at room temperature. After washing, secondary antibody
Alexa Fluor 488 goat anti-mouse IgG (H+L) or Alexa Fluor 633
goat anti-rat IgG (H+L) (Invitrogen) was added for 1 h to detect
the bound primary antibody. Washing subsequently removed
unbound antibody and samples were analysed using fluorescent
activated cell sorting.
Laser scanning confocal microscopy
Protoplasts expressing either human claudin-1 or no heterolo-
gous human proteins (X33) were seeded onto glass coverslips. The
protoplasts were immuno-flourescently labelled for human clau-
din-1 (anti-claudin-1, R&D systems) or a non-specific IgG (anti-
mouse IgG). Confocal optical sectioning (45 Z sections, 0.42 mm)
was performed on an upright Zeiss 780 laser scanning confocal
microscope using a 10061.4NA objective. Microscope settings
were optimized for each fluorescent protein to obtain the highest
signal to noise ratio, while controlling for cross talk. 3D
reconstructions of the 16 bit optical sections were performed
using the Carl Zeiss ZEN software.
Western blotting
Yeast membranes were prepared from 20 g wet cells suspended
in 40 mL sterile ice-cold breaking buffer (50 mM sodium
phosphate buffer, 2 mM EDTA, 100 mM NaCl, 5% glycerol
(w/v), pH 7.4) and protease inhibitors (cocktail set IV, Calbio-
chem). Cells were passed through an Emulsiflex-C3 cell disrupter
until .90% breakage was observed under a light microscope.
Figure 8. Proposed assembly of claudin-1/CD81 complexes
(RH=30 nm). A cartoon assembled in ChemDraw illustrating seven
uroplakin-like CD81 complexes (black), each containing six homodi-
mers, arranged with 24 claudin-1 homodimers (red). The resulting molar
ratio of 24:42 claudin-1:CD81 is close that observed experimentally
(Table 1), and generates a RH= 30 nm particle. The model displayed is
the most symmetric of those generated.
doi:10.1371/journal.pone.0064517.g008
Figure 7. Claudin-1/CD81 complexes are stabilized by CHEMS. (A) A plot of relative intensity of differently-sized particles (RH reported in nm)
is shown for the claudin-1/CD81 1:2 mix with (closed circles) and without (open circles) CHEMS. (B) The stable RH = 30 nm particle forms within a few
minutes of mixing and is stable in the presence of CHEMS for 18 h. In the absence of EC1, aggregation occurs after 4 h.
doi:10.1371/journal.pone.0064517.g007
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Unbroken cells and cell debris were removed by centrifugation
(10,0006 g, 30 min, 4uC) and the supernatant was collected and
ultracentrifuged (100,0006 g, 90 min, 4uC) to isolate the total
membrane fraction. The yeast membrane pellet was suspended in
sterile ice-cold buffer (20 mM HEPES, 50 mM NaCl, 10%
glycerol, pH 7) using a glass homogenizer. Membrane fractions
were kept on ice if used for immediate analysis or snap-frozen in
liquid nitrogen and stored at 280uC. For reducing SDS-PAGE
total membrane samples were heated at 98uC for 10 min in
sample buffer (50% distilled water, 12.5% 0.5M Tris-HCl
(pH 6.8), 10% glycerol, 2% SDS, 5% b-mercaptoethanol and
0.001% bromophenol blue). Non-reducing SDS-PAGE samples
were prepared using the same buffer without the addition of b-
mercaptoethanol. Samples were separated using a 12% Tris-HCl
gel and transferred to a nitrocellulose membrane before immu-
noblotting with a primary monoclonal antibody (anti-His6,
Clontech) followed by an anti-mouse IgG HRP-conjugated
secondary antibody (Sigma). EZ-ECL chemiluminescence (Gene-
flow) was used to detect protein bands.
Huh-7.5 hepatoma cells (the kind gift of Charles Rice, The
Rockefeller University [47]; seeded the preceding day at
1.56104 cm22) were harvested in lysis buffer (PBS, 1% Triton-
X100, 0.1% sodium deoxycholate, 0.1% SDS) containing protease
inhibitors (Complete, Roche, UK). Cell lysates were clarified by
centrifugation (20,0006 g, 30 min) and the protein concentration
determined using Protein Assay Reagent (Pierce) according to
manufacturer’s instructions. Quantified protein lysates were
separated by 12% SDS-PAGE and transferred to PVDF
membranes (Sigma, UK) for incubation with anti-claudin-1
(MH25, Invitrogen). Secondary antibodies, horseradish peroxi-
dase-conjugated donkey anti-rabbit, were detected by enhanced
chemiluminescence (Geneflow, UK).
Quantitative ELISA
Purified tetraspanin proteins or enriched membranes were
allowed to bind Immulon II ELISA plates (Nunc) at 1 mg mL21
for 4 h at 37uC. Unbound protein was removed by washing with
PBS, the plates were blocked with 5% bovine serum albumin-PBS
and bound protein detected with anti-receptor antibodies and anti-
species, immunoglobulin-horseradish peroxidase conjugate (Jack-
son Laboratories) and tetramethylbenzidene (BioFX Laboratories).
In parallel, tetraspanin proteins were evaluated for their ability to
bind recombinant HCV E2. HCV E2661 strain H77 was used at
1 mg mL21 by incubating at 37uC for 2 h and bound antigen
detected with anti-E2 3/11, as previously reported [48]. Absor-
bance values were measured at 450 nm on a Fusion Plate Reader
(Perkin-Elmer).
Purification of recombinant claudin-1, CD81 and CD82
CD81 and CD82 were extracted from yeast membranes using
3% bOG (Anatrace) at 15uC for 1 h. Claudin-1 was solubilised
using 3% bOG [20,45], 3% profoldin-8 or 3% foscholine-10
(Anatrace) at 15uC for 16 h. Solubilized proteins were purified
using HisTrap HP sepharose (GE Healthcare) with elution at
500 mM imidazole [20,45]. Eluted fractions were concentrated at
10uC using a VivaSpin20 column, with a 10 kDa cut-off, prior to
loading onto a HiLoad Superdex S200 gel filtration column, also
equilibrated at 10uC. Proteins were eluted in 10 mM MOPS
pH 8, 1% bOG at a flow rate of 0.2 mL min21. Purity and yield
were assessed using Coomassie blue staining of SDS-PAGE gels.
Gels were also silver stained (SilverStainPlus, BioRad) and the
identity of the 4TM proteins was confirmed by immunoblot using
specific antibodies for CD81 [49] and claudin-1 (Zymed; 51-9000).
The yield of purified CD81 and CD82 from 2 g wet weight of
membranes, solubilized in 20 mL 3% detergent solution, was
approximately 2 mg, whilst the corresponding yield of claudin-1
was approximately 0.3 mg. Multiple protein preparations were
generated during this study to enable subsequent analyses.
Biophysical analysis of purified 4TM proteins
A Beckman XLI analytical ultracentrifuge using an 8 cell 50Ti
rotor was used for the AUC studies according to [20]. A total of
100 measurements were taken throughout each 8 h run. Data
from each experiment were analyzed using the continuous c(s)
distribution model implemented within SEDFIT94. Parameters
for the partial specific volume of the protein, buffer viscosity and
density were calculated using SEDNTERP [20]. CD spectra were
recorded using a JASCO J-810 nitrogen-flushed spectropolarim-
eter, as previously described [20].
Biological analysis of claudin-1
Proteoliposomes were generated from purified, recombinant
claudin-1 (profoldin-8-extracted and purified) and CD82 (bOG-
extracted and purified) as previously described [24] using
cholesterol:sphingomyelin:1,2-dioleoyl-sn-glycero-3-phosphocho-
line at a molar ratio of 24:37:37. Lipids were mixed with protein at
a molar ratio of 5,000:1 at room temperature in the presence of
1.6% b-OG in 1 mL 25 mM HEPES pH 7.5, 150 mM NaCl.
Proteoliposomes were recovered by flotation in an OptiPrep
gradient. Dialyzed and pooled proteoliposomes were used for
subsequent viral assays. SDS-PAGE and silver staining confirmed
they contained protein; the lipid composition of the proteolipo-
somes was 30% cholesterol, 55% sphingomyelin, 15% 1,2-
dioleoyl-sn-glycero-3-phosphocholine. For viral infection assays,
HCV J6/JFH was generated as previously described [50]. Briefly
RNA was transcribed in vitro from full-length genomes (RiboMax
T7 kit, Promega) and electroporated into Huh-7.5 cells. Viral
stocks were generated by two sequential passages through Huh-7.5
cells. Supernatants were collected, pooled, and stored at 280uC.
Infected cells were detected by methanol fixation and staining for
HCV encoded NS5A using monoclonal antibody, 9E10 (a gift of
Charles Rice and Tim Tellinghuisen Rockefeller University,
USA); bound antibody was detected with anti-mouse IgG Alexa-
488 and quantified by enumerating NS5A expressing cells.
Pseudoviruses expressing a luciferase reporter were generated as
previously described [51]. Briefly, 293T cells were transfected with
a 1:1 ratio of plasmids encoding HIV provirus expressing
luciferase and HCV strain H77 E1E2 envelope glycoproteins
(HCVpp), vesicular stomatitis virus G glycoprotein (VSV-Gpp) or
empty vector (Env-pp). Supernatants were harvested 48 h post
transfection. Infection was quantified by measuring luciferase
activity (relative lights units, RLU) and specific infectivity
determined by subtracting the mean Env-pp signal from the
HCVpp, or VSV-Gpp values. HCVcc or HCVpp were allowed to
infect Huh-7.5 cells in the presence or absence of proteoliposome
preparations for 6 h and unbound virus removed by washing and
the cells fed with 3% FBS/DMEM. Infections were allowed to
proceed for 72 h and enumerated by counting NS5A expressing
cells or luciferase activity, respectively.
Analysis of complex formation by size exclusion
chromatography and DLS
Initial analysis of complex formation was done by size exclusion
chromatography (Superdex S200 10/300 GL; column volume
24 mL) on solubilized proteins alone and after incubation
together. Subsequently, DLS measurements were used to assess
whether complexes had formed. Prior to mixing, to avoid
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disturbances to the DLS measurements, aggregates and dust
particles were removed from the purified protein solutions (0.3–
0.4 mg mL21) by filtration through a 0.1 mm filter, followed by
clarification at 14,0006 g. Proteins were then transferred to an
MRC crystallization plate (96-well SBS format, Swissci AG,
Switzerland) at 1 mL/well. Five different molar ratios of claudin-1/
CD81, claudin-1/CD82 and claudin-1/claudin-1 (9:1; 2:1; 1:1;
1:2; 1:9) were analyzed with and without the addition of 0.1 mL
CHEMS (2.2 mg mL21 in 20 mM MOPS, pH 8, 1% beta-OG)
to the drop. As controls, claudin-1, CD81 and CD82 were
analyzed alone, with and without addition of 0.1 mL CHEMS
(2.2 mg/mL in 20 mM MOPS, pH 8, 1% bOG) to the drop, as
well as the same buffer without protein. The reservoirs were filled
with 35 mL protein buffer (20 mM MOPS, pH 8, 1% beta-OG)
and the plate was sealed with SmartSeal (Greiner Bio-One
GmbH, Germany) to avoid evaporation during the measurements.
DLS measurements within these droplets were carried out at 20uC
using a Spectro Light 500 instrument (XtalConcepts GmbH,
Germany), a plate reader for UV/visible-imaging and in situ
DLS [52]. Data were analyzed using Spectro (Nabitec GmbH,
Germany). Spectro interprets the autocorrelation function (ACF)
[53] using the CONTIN-algorithm [30] to obtain the distribution
of particle radii. To obtain data on the time-dependent change of
the hydrodynamic radius (RH) distribution of the respective
protein mixtures, DLS measurements were recorded for 23–36 h
in all wells. From each well a series of 130 measurements at 30 s
per measurement was recorded, with an interval of approximately
10 min between each measurement.
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